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There is a lack of updated nationwide records
regarding hepatitis C virus (HCV) infection
among drug addicts in Italy. The prevalence
and characteristics of HCV infection in a nation-
al sample of drug addicts in Italy were deter-
mined. Five hundred forty-three drug addicts
(mean age 35.3 years, 85.1% males), selected
from 25 Italian Centers for Substance Depen-
dence were enrolled to be evaluated for anti-
HCV, HCV-RNA, HCV genotype, HBV markers,
anti-HDV, and anti-HIV during the period of
April–November 2009. Anti-HCV prevalence
was 63.9%. HCV-RNA was detected in 68.3% of
patients positive for anti-HCV. Genotypes 1 and
3 prevailed (49.3% and 39.7%, respectively).
However, 9.3% of the subjects had genotype 4,
a rate over threefold higher than the one ob-
served in 1996 among drug addicts in central
Italy. Needle sharing was the strongest inde-
pendent predictor of the likelihood to contract
an HCV infection (OR 8.9; 95% CI: 5.0–16.0).
Only 19.3% of subjects received antiviral treat-
ment for HCV. The prevalence of HBsAg and
HIV positivity was 2.8% and 3.1%, respectively.
The pattern of HBV markers showed that nearly
one-third of subjects had been vaccinated,
while 42.3% were negative for any marker of
HCV. The prevalence of HCV infection is high
among drug addicts in Italy. The incidence of
Genotype 4 is increasing and this may lead to
the spreading of the disease to the general pop-
ulation in the near future. Efforts should be
made to improve the rate of antiviral treatment
for drug addicts with HCV infection and vacci-
nation against hepatitis B. J. Med. Virol. 84:
1608–1612, 2012.  2012 Wiley Periodicals, Inc.
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INTRODUCTION
Intravenous drug use is one of the most efﬁcient
transmission routes of hepatitis C virus (HCV) infec-
tion. It is estimated that worldwide about 10 million
(range: 6.0–15.2) intravenous drug users might be
anti-HCV positive, and that many more are anti-HCV
positive compared to the number of individuals with
HIV infection [Nelson et al., 2011]. Despite the fact
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that drug users represent a wide segment of subjects
with chronic HCV infection they are often excluded
from treatment with interferon (IFN) because of con-
cerns about adherence, re-infection, and IFN-mediated
neuropsychiatric toxicity.
Italian data on HCV prevalence among drug addicts
reveal a 32–84% range of HCV positivity [Stroffolini
et al., 1997; Quaglio et al., 2003; Sereno et al., 2009].
Nevertheless, these data are either outdated or de-
rived from local studies. Consequently, considering
the complexity of the clinical management in this cat-
egory of patients, it is important to deﬁne an updated
epidemiological picture in Italy.
The aim of this study was to assess the prevalence
and characteristics of HCV positivity among a repre-
sentative national sample of drug addicts monitored
by Services for Substance Dependence of the Italian
National Health System. The prevalence of HBV,
HDV, HIV, and their respective HCV coinfection were
also evaluated.
PATIENTS AND METHODS
This multicenter, observational, cross-sectional
study enrolled consecutive drug addicts (both intrave-
nous and non-intravenous drug users) from 25 Italian
rehabilitation centers distributed widely all over the
country during the period of April–November 2009.
The study inclusion criteria were subjects aged 18-
to 65-year old who satisﬁed the criteria for substance
dependence according to the Diagnostic Manual of
Mental Disorders, Fourth Edition (DSM-IV-TR) [Diag-
nostic and Statistical Manual of Mental Disorders,
2000]. Exclusion criteria were alcohol dependence and
participation in any other clinical study. The study
consisted of a single visit during which all the study-
related procedures were performed under the full con-
trol and responsibility of the Investigator. Procedures
included the collection of demographic data, medical
history, assessment, and evaluation of current and
past drug addiction.
A written informed consent to study participation
and to the treatment of personal data (according to
the Italian Privacy law) was provided to all subjects
by the investigator, and a speciﬁc form which was dat-
ed and signed by each patient was obtained before en-
tering the study. Approval of the Ethics Committee
was required from each site before the study began.
Virologic Assays
A 10 ml blood sample was collected from each par-
ticipant within 7 days of the study visit. Local labora-
tories performed the alanine aminotransferase (ALT)
test. An aliquot of blood was stored at 208C and then
sent to the study central laboratory Laboraf in Milan,
Italy, for virologic assays. All samples were tested for
HBV markers (HBsAg, HBeAg, anti-HBc, and anti-
HBs), and anti-HCV using the Chemiluminescent
Microparticle ImmunoAssay (CMIA) method (Architect,
Abbott Laboratories, Abbott Park, IL). All samples
were tested for anti-HDV by enzyme-linked immuno-
sorbent assay (ELISA) method (test ETI-AB-DEL-
TAK-2, Diasorin, Saluggia, Italy). Positive sera for
HCV were tested for HCV-RNA by PCR (PCR real-
time—detection limit 12 IU/ml; Abbott Laboratories).
HCV-RNA positive sera were further tested for geno-
typing that was obtained by direct sequencing of the
50-untranslated terminal region (50UTR) gene of HCV
followed by an analysis performed with a web-based
automated genotyping program using BLAST, which
can be found at http://www.ncbi.nlm.nih.gov/projects/
genotyping/formpage.cgi.
Statistical Analysis
Differences in proportion and means were calculat-
ed by chi-squared test or Student’s t-test, respectively.
A P < 0.05 value was considered to be signiﬁcant. A
univariate analysis was used to estimate the crude
odds ratios (OR) for the association between different
variables and anti-HCV positivity. Adjusted OR were
calculated by multiple logistic regression analysis
[Kleinbaum et al., 1982] to identify independent pre-
dictors of the likelihood of anti-HCV positivity. In the
logistic model, anti-HCV positivity was the outcome
variable, while age, educational level, needle ex-
change, sexual partners of intravenous drug users,
past detention, and intravenous use of heroin or co-
caine were the independent variables. The reference
category for estimates was that of the most favorable
level of exposure.
RESULTS
A total of 558 subjects were enrolled and provided
informed consent. Fifteen subjects were excluded from
the analysis because of a missing anti-HCV test.
Thus, the total number of subjects evaluated was 543.
Table I shows the baseline characteristics of the en-
rolled subjects. Almost all subjects were Caucasian
(98.0%) and mean age was 35.3 years. There was a
clear male predominance (85.1%). Subjects came from
all over Italy with a slight prevalence of the northern
regions. Only 3.5% had completed university studies.
The majority (85.5%) of subjects lived in households of
no more than four people. Eighty-three percent went
to their local rehabilitation center for substance
dependence independently and were not referred by
others. Only 7.6% of subjects had started drug abuse
within the last 5 years. The subjects declared that, at
the time of study, they were consuming heroin
(59.5%), cocaine (45.7%), or cannabis (47.0%).
Virologic assays showed that the prevalence of anti-
HCV positivity (including subjects with coinfections)
was 63.9%. HCV-RNA was detected in 68.3% of
patients who were anti-HCV positive. Genotypes 1
and 3 prevailed (49.3% and 39.7%, respectively) even
though the proportion of subjects infected by genotype
4 reached the rate of 9.3%. The prevalence of HBsAg
and anti-HIV positivity was 2.8% and 3.1%, respec-
tively. Of the 15 HBsAg positive subjects, only one
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(6.7%) was HBeAg positive, and three (20.0%) were
co-infected with HDV. The percentage of HBsAg
detected in subjects with anti-HCV positivity was
2.2%, while the percentage of subjects positive for
both anti-HCV and anti-HIV was 3.0% (Table II).
Table III shows a comparison of sociodemographic
characteristics of subjects with HCV infection. Anti-
HCV positive subjects were more likely to be older
(37.4 years vs. 31.6 years; P < 0.001), with a low edu-
cation level, and living in smaller households com-
pared to participants not infected by HCV. Subjects
with anti-HCV positivity also had a signiﬁcantly lon-
ger duration of drug exposure and were more likely to
report intravenous use of heroin and cocaine. Addi-
tional potential risk factors of exposure to HCV (ex-
change of needles or other drug paraphernalia, sexual
partners of intravenous drug users vv. previous deten-
tion) were reported more frequently by subjects with
anti-HCV positivity (Table IV). Eighty-seven percent
of anti-HCV positive subjects were conscious of their
liver disease, but only 67 out of 347 (19.3%) anti-HCV
positive subjects had received a speciﬁc antiviral
treatment (data not shown).
Table V shows the crude and adjusted OR for the
association between potential risk factors and anti-
HCV positivity. A univariate analysis of all variables
versus anti-HCV positivity was performed. After
adjustment for the confounding effect of all variables
included into the model, we observed that age >36 years,
needle exchange, past detention, intravenous use of
heroin and cocaine all resulted as independent pre-
dictors of the likelihood of anti-HCV positivity. Low
education level and intravenous drug user sexual
partners were not associated with HCV infection.
Finally, the pattern of HBV markers among the 543
drug addicts was as follows: 230 subjects (42.3%) were
negative for all HBV markers, 15 (2.8%) were HBV
positive, 68 (12.5%) displayed a resolved previous
infection and were anti-HBs/anti-HBc positive, 44
(8.1%) were anti-HBc positive only, and 186 (34.3%)
subjects who had been vaccinated against HBV were
anti-HBs positive only.
DISCUSSION
This study provides a national picture of HCV infec-
tion among Italian drug users. Nearly two-thirds of
the subjects included in this observational study were
anti-HCV positive. The ﬁgures are similar throughout
all the geographical areas suggesting a nationwide
distribution of the issue. The majority of subjects had
detectable HCV-RNA and nearly 50% resulted as
>600,000 IU/ml. As expected, a great percentage
(39.7%) of subjects was infected by genotype 3. How-
ever, 9.3% were infected by genotype 4, a rate over
threefold higher than the one observed in 1996 in a
study performed in Central Italy [Stroffolini et al.,
1997]. This increase in the past 13 years suggests
that genotype 4 is spreading among drug users in
Italy. Given that this group of subjects is relatively
young, genotype 4 may further spread to the general
population in the near future. Drug addiction seems
to be the key factor for the introduction and spreading
of genotype 4 in the western world [Schro¨ter et al.,
2002]. A French survey has shown that in Paris,
TABLE I. Baseline Characteristics of Subjects Included in
the Study
Variable n ¼ 543
Age (years) (mean  SD) (range) 35.3  8.6 (18–62)
Gender
Male 462 (85.1%)
Female 81 (14.9%)
Italian area of origin
North 216 (39.8%)
Center 149 (27.4%)
South/Islands 178 (32.8%)
Education
Elementary school 57 (10.5%)
Middle school 317 (58.4%)
High school 150 (27.6%)
College degree 19 (3.5%)
Family members
4 464 (85.5%)
>4 79 (14.5%)
Referral pattern
Volunteer 451 (83.0%)
Family 38 (7.0%)
Social services/police 27 (5.0%)
Other 27 (5.0%)
Time since first drug exposure
5 years 41 (7.6%)
6–10 years 112 (20.6%)
11–20 years 198 (36.4%)
>20 years 192 (35.4%)
Current drug abusea
Heroin 323 (59.5%)
Cocaine 248 (45.7%)
Cannabis 255 (47.0%)
aMultiple reply.
TABLE II. Virologic Characteristics of Subjects Included in
the Study
Viral marker n ¼ 543
Anti-HCV positive (including coinfections) 347 (63.9%)
HCV-RNA positivea 237 (68.3%)
HCV-RNA 600,000 IU/mlb 134 (56.5%)
HCV genotypesc
1 117 (49.3%)
1a 56 (47.9%)
1b 27 (23.1%)
1c 34 (29.0%)
2 4 (1.7%)
3 94 (39.7%)
4 22 (9.3%)
HBsAg positive (including coinfections) 15 (2.8%)
HBeAg positived 1 (6.7%)
Anti-HDV positived 3 (20.0%)
Anti-HIV positive (including coinfections) 17 (3.1%)
Anti-HCV/HBsAg positive 12 (2.2%)
Anti-HCV/anti-HIV positive 16 (3.0%)
aIn anti-HCV positive.
bData not available for all subjects.
cIn HCV-RNA positive.
dIn HBsAg positive.
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genotype 4 is responsible for more than 10% of HCV
cases [Payan et al., 2005]. Furthermore, a high preva-
lence of genotype 4 (23.4%) has been found among
HCV-infected Polish drug users [Chlabicz et al.,
2008]. The distribution of HCV genotypes is of partic-
ular importance, since it represents a key factor of
response to treatment. In fact, genotype 4 shows a
lower response rate to antiviral treatment compared
to genotype 3 [Khattab et al., 2011].
A major concern that emerged from this study is
that only 1 out of 5 subjects with anti-HCV positivity
had received a speciﬁc treatment for HCV infection.
This is in contrast with recent studies that demon-
strated a rate of sustained virologic response in drug
addicts comparable to that achieved among non-drug
addicts [European Association for the Study of the
Liver, 2011].
As expected, the route by which a drug was admin-
istered inﬂuenced the rate of HCV positivity. Subjects
reporting needle exchange are 9.2 times more likely to
be anti-HCV positive than those who denied this
practice.
In this cohort of drug addicts, the prevalence of
HBV and anti-HIV positivity resulted unexpectedly
low. Despite the fact that vaccination of drug users
has been strongly recommended [Almasio et al., 2011]
and offered free of charge in Italy since 1984, only
one-third of these subjects were actually vaccinated
against HBV. Therefore, approximately half of en-
rolled subjects were still susceptible to HBV and thus
at risk of infection.
In conclusion, this observational study shows a high
prevalence of HCV infection but low rates of other
parenterally transmitted viruses among drug addicts
in Italy. The prevalence of Genotype 4 is rising among
this group of people, and, consequently, it might
spread to the general population in the near future.
Efforts should be made to improve the rate of
TABLE III. Comparison of Demographic Characteristics of Subjects With HCV Status
Variable Anti-HCV positive (n ¼ 347) Anti-HCV negative (n ¼ 196) P-value
Age (years) (mean  SD) 37.4  8.1 31.6  8.4 <0.001
Gender
Male 296 (85.3%) 166 (84.7%) 0.8
Female 51 (14.7%) 30 (15.3%)
Italian area of origin
North 132 (38.0%) 84 (42.9%) 0.5
Center 97 (28.0%) 52 (26.5%)
South/Islands 118 (34.0%) 60 (30.6%)
Education
Elementary school 42 (12.2%) 15 (7.7%) 0.01
Middle school 213 (61.4%) 104 (53.1%)
High school 83 (23.9%) 67 (34.2%)
College degree 9 (2.6%) 10 (5.1%)
Family members
4 307 (88.5%) 157 (80.1%) 0.008
>4 40 (11.5%) 39 (19.9%)
Referral pattern
Volunteer 282 (81.3%) 169 (86.2%) 0.2
Family 29 (8.4%) 9 (4.6%)
Social Services/police 16 (4.6%) 11 (5.6%)
Other 20 (5.7%) 7 (3.6%)
ALT levelsa
Normal 150 (44.4%) 171 (88.6%) <0.001
Abnormal 188 (55.6%) 22 (11.4%)
aData not available for all subjects.
TABLE IV. Characteristics of Drug Addiction and Potential Risk Factors According to Anti-HCV Condition
Variable Anti-HCV positive (n ¼ 347) Anti-HCV negative (n ¼ 196) P-value
Time from first drug exposure
5 years 11 (3.2%) 30 (15.3%) <0.001
6–10 years 50 (14.4%) 62 (31.6%)
11–20 years 133 (38.3%) 65 (33.2%)
>20 years 153 (44.1%) 39 (19.9%)
Intravenous use of heroin 158 (45.5%) 27 (13.8%) <0.001
Intravenous use of cocaine 90 (27.7%) 6 (3.1%) <0.001
Paraphernalia/syringe exchange 194 (56.1%) 18 (9.2%) <0.001
Transfusion 20 (5.8%) 8 (4.1%) 0.4
Intravenous drug user sexual partners 108 (31.1%) 27 (13.8%) <0.001
Past detention 129 (37.2%) 39 (19.9%) <0.001
Multiple risk factors for the same subject.
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antiviral treatment for drug addicts with HCV infec-
tion and vaccination against hepatitis B.
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